SAN DIEGO, Dec. 20, 2016 /PRNewswire/ -- ResMed (NYSE: RMD)
today announced that industry leader Carlos
M. Nunez, MD, will become ResMed's chief medical officer,
effective January 3, 2017.
Nunez most recently served as senior vice president of medical
affairs for Becton, Dickinson and Company. He will be based in
ResMed's San Diego headquarters
and will report directly to CEO Mick
Farrell and President/COO Rob
Douglas.
"I'm delighted to welcome Carlos
Nunez to ResMed," said Farrell. "Carlos has great depth in
clinical and medical technology, and great breadth in healthcare
informatics and business management. His proven leadership
capabilities and track record of collaboration across global teams
make him an ideal addition to our executive team. Carlos will play
a key role in accelerating ResMed's 2020 growth strategy, including
clinical trials of sleep apnea, neuromuscular disease and COPD, as
well as in connected care."
Dr. Nunez joins ResMed with two decades of leadership experience
in the medical field, with a focus on aligning the clinical
realities of modern healthcare with the business strategies of
global enterprises. As senior vice president of medical affairs for
BD, he drove business strategy, innovation and public policy
efforts across a business with $12
billion in revenue, while advising on safety, quality and
regulatory matters. He has also held senior leadership positions at
United HealthCare Group's Optum division, CareFusion and Picis, a
healthcare informatics company.
"As an industry leader in the treatment of sleep-disordered
breathing, chronic obstructive pulmonary disease and other chronic
diseases, ResMed is tackling some of society's largest healthcare
challenges with a unique mixture of top-quality devices and
software," said Dr. Nunez. "I'm looking forward to working with
ResMed's global team to translate emerging clinical research into
the next wave of products, services, and solutions that even better
treat chronic respiratory diseases, keep patients out of the
hospital, save time and money for providers and payers, and
ultimately improve patient outcomes."
ResMed's current chief medical officer, Dr. Glenn Richards, will transition to the role of
medical director for the company's product development
teams. Dr. Richards will continue to provide clinical support
and leverage his vast experience to create even greater value for
ResMed customers and their patients.
"Glenn is a pioneer in the field of sleep medicine and has led
our global medical team with passion and dedication. He has helped
as we have evolved ResMed from the world's leading respiratory
medical device company to our position today as the world's leading
tech-driven medical device company," said Mick Farrell. "We are grateful for Glenn's hard
work and his contributions to ResMed and the field of respiratory
medicine over more than two decades. Our team is thrilled that
Glenn will continue to help steward ResMed's medical path forward
in his new role as medical director."
Additional Background on Carlos
Nunez, MD
Dr. Nunez led medical affairs for
Becton Dickinson and Company's
medical segment since 2015. Before that, he was the chief medical
officer and SVP medical affairs for CareFusion, a global medical
technology company specializing in acute respiratory care, reducing
medication errors and the prevention of healthcare-associated
infections. During this time, he built and led a multidisciplinary
team that provided medical authority and oversight for all of the
businesses and functions of the multinational medical device and
pharmaceutical company. From 2000 to 2010, Nunez was the chief
physician executive for medical informatics company Picis, Inc.
While at Picis, he provided medical leadership and clinical
direction for corporate strategy, marketing, product development,
sales, implementation and customer relations in both domestic and
international markets. Before that, he was the director of critical
care education and research at Carolinas Medical Center Northeast
in Concord, North Carolina. Nunez
is a board-certified anesthesiologist. He received his MD from the
University of Miami's Leonard M. Miller School of Medicine where he
also completed his postgraduate training in anesthesiology,
critical care medicine and clinical research.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 2 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
For
media:
|
For
investors:
|
Alison
Graves
|
Agnes Lee
|
Director, Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://mma.prnewswire.com/media/450864/resmed_Logo.jpg